Lupin Ltd
Lupin Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #60 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Lupin Ltd Q2 FY27 key numbers
- Revenue
- Q2 FY27 Net Sales: ₹77,855 million, up 14.0% YoY.
As stated in Lupin Ltd's Q2 FY27 investor presentation · published 4 Nov 2026. Reported figures, not investment advice.
Based on Lupin Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Net Sales: ₹77,855 million, up 14.0% YoY (Page 13). EBITDA for Q2 FY27: ₹19,574 million, with a year-on-year (YoY) change of +8%.
From Lupin Ltd's Q2 FY27 earnings-call transcript · updated 4 Nov 2026.
How did Lupin's revenue grow in the September 2026 quarter?
- Q2 FY27 Net Sales: ₹77,855 million, up 14.0% YoY (Page 13)
- Q2 FY27 Total Revenue: ₹78,273 million, up 11.1% YoY (Page 13)
- EBITDA for Q2 FY27: ₹19,574 million, down 8.4% YoY (Page 13)
- Net Income for Q2 FY27: ₹11,553 million, down 21.8% YoY (Page 13)
- India sales for Q2 FY27: ₹23,836 million, up 15% YoY (Page 7)
- US sales include IP income: ₹30,202 million (Page 7)
- LATAM sales: ₹2,427 million, up 30% YoY (Page 5)
- EMEA sales: ₹9,913 million, up 40% YoY (Page 5)
- APAC sales: ₹4,273 million, up 43% YoY (Page 5)
2 more points from Lupin Ltd's call on revenue
Create a free account to keep reading this call
What happened to Lupin's margins in Q2 FY27?
See what Lupin Ltd said on profitability & margins — free account, 30 seconds.
What capex is Lupin planning?
- Page 18 (FY26 Sustainability Update) notes zero waste to landfill external certification for manufacturing sites (7 Platinum, 1 Gold), implying capex in waste management.
- Q2 FY27 Key Developments (Page 6) mention:
- Mandideep Unit I received ANVISA approval (Brazil).
2 more points from Lupin Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Lupin raising money or cutting debt?
See what Lupin Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Lupin's order book?
See what Lupin Ltd said on order book & pipeline — free account, 30 seconds.
Lupin Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹7.5K Cr, net profit ₹1.5K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lupin's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Glaxosmithkline Pharmaceuticals (Q2 FY27)
97,994 lakhs in the corresponding quarter of 2025, reflecting a year-on-year increase of approximately 20.8%. Key results statement takeaways from Glaxosmithkli
- Remus Pharmaceuticals (Q2 FY27)
Standalone Revenue (H1 FY27 vs H1 FY26):** ₹62.08 Cr vs ₹46.85 Cr, growth of 32.51% . Key results statement takeaways from Remus Pharmaceuticals Ltd's Q2 FY27 e
- Amrutanjan Healt (Q2 FY27)
Q2 FY27 Net Sales:** ₹135.18 Crores, up 14.85% YoY (₹117.70 Crores in Q2 FY26) . Key investor presentation takeaways from Amrutanjan Health Care Ltd's Q2 FY27 i
- Pfizer (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026: ₹726.86 crore (Page 3). Key results statement takeaways from Pfizer Ltd's Q2 FY27 results stat
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Lupin Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Lupin Ltd Q2 FY27 results?
Q2 FY27 Net Sales: ₹77,855 million, up 14.0% YoY (Page 13). EBITDA for Q2 FY27: ₹19,574 million, with a year-on-year (YoY) change of +8%.
What is Lupin Ltd share price analysis?
Lupin Ltd currently shows a neutral. The stock trades at a P/E of 15.5 with a market cap of ₹92,186 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Lupin Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.